Who Paid My Doc
Kashif Latif
Bartlett, TN Medical Doctor
NPI 1902913692 CMS profile 268402
3025 Kate Bond Rd, Bartlett, TN 38133
General payments
$269,620
Research payments
$124,623
Ownership & investment interest
$0
Research they led as principal investigator
$780,876
Through program year 2025, Kashif Latif of Bartlett, TN is reported in the CMS Open Payments database as having received $269,620 across 1,302 general payments and $124,623 in research payments paid to them. Separately, studies naming them as principal investigator received $780,876 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
11 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $115,921 | 243 | |
| 2025 | Research | $1,555 | 11 | |
| 2024 | General | $66,570 | 217 | |
| 2024 | Research | $78,683 | 2 | |
| 2023 | General | $45,533 | 191 | |
| 2023 | Research | $44,040 | 3 | |
| 2022 | General | $5,678 | 169 | |
| 2021 | General | $6,820 | 117 | |
| 2021 | Research | $345 | 2 | |
| 2020 | General | $6,905 | 177 | |
| 2019 | General | $22,193 | 188 |
Beside peers
- Kashif Latif
- Tennessee median
- Middle half of Tennessee
- National median
In program year 2025, general payments to Kashif Latif were reported at $115,921. Among 24,836 Tennessee profiles paid that year, the median was $199 and the middle half received between $54 and $728.
Show as a table
| Year | Kashif Latif | Tennessee median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $22,193 | $197 | $58–$789 | $163 |
| 2020 | $6,905 | $132 | $38–$484 | $114 |
| 2021 | $6,820 | $145 | $39–$541 | $132 |
| 2022 | $5,678 | $170 | $50–$642 | $149 |
| 2023 | $45,533 | $183 | $50–$668 | $160 |
| 2024 | $66,570 | $187 | $51–$700 | $164 |
| 2025 | $115,921 | $199 | $54–$728 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 162 drugsPart D claims
13,748
Drug cost
$5,874,727
Branded share of claims
52.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 1,004 | $1,378,396 | |
| Mounjaro Tirzepatide | Brand | 663 | $949,461 | |
| Jardiance Empagliflozin | Brand | 487 | $575,634 | |
| Trulicity Dulaglutide | Brand | 272 | $456,827 | |
| Farxiga Dapagliflozin Propanediol | Brand | 331 | $348,340 | |
| Tresiba Flextouch U-100 Insulin Degludec | Brand | 430 | $309,157 | |
| Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 | Brand | 188 | $293,228 | |
| Tresiba Flextouch U-200 Insulin Degludec | Brand | 103 | $114,341 | |
| Xigduo Xr Dapaglifloz Propaned/Metformin | Brand | 112 | $107,569 | |
| Synjardy Xr Empagliflozin/Metformin Hcl | Brand | 99 | $102,258 |
The 10 drugs with the highest cost, of 162 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 120 billing codesPaid by Medicare
$692,433
Medicare patients
1,253
Services billed
33,134
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 71% | |
| Arthritis | 48% | |
| Ischemic heart disease | 36% | |
| Chronic kidney disease | 34% | |
| Depression | 18% | |
| Osteoporosis | 18% | |
| Heart failure | 16% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 | Office | 25 | 25 | $548 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 | Office | 18 | 1,900 | $184 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 | Office | 18 | 53 | $43 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 28 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| TZIELD |
|
$41,720 | — | — |
| AFREZZA |
|
$3,221 | 11 | — |
| JARDIANCE |
|
$358 | 487 | — |
| Korlym |
|
$198 | — | — |
| Wegovy |
|
$183 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See more in the dashboard: 25 with a free account, all 28 with PatronRecords
1,320 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.